Ribavirin for Chronic Hepatitis E in Liver-Transplant Setting: A Safe and Highly Effective Therapy

Carmo, Joana; Marques, Susana; Mateus, Élia; Morbey, A.; Veloso, J. A. F.; Almeida-Santos, Madalena; Curran, Martin D.; Barroso, Eduardo

doi:10.1097/mcg.0000000000000554

Cited by 5 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, 27 studies 5,14,15,18,22,26–47 were evaluated for the second arm on HEV treatment, including 118 LT recipients (6 of them with dual liver/kidney and 1 with liver/heart recipients) treated with various regimens for HEV infection (Table 3).…”

Section: Resultsmentioning

confidence: 99%

“…Five studies 10,25–28 evaluated HEV prevalence in 379 LT patients with abnormal LFTs (median age ranged from 50 to 58 years) Table 2, Figure 3. Four studies were from Europe (Spain: 1, Germany: 2, Portugal:1) and 1 from Asia (Hong Kong).…”

Section: Resultsmentioning

confidence: 99%

“…One study ( n = 70, 18%) evaluated both serum HEV Abs (IgG, IgM) and HEV RNA, 10 two studies [ n = 143, 38%] evaluated only HEV Abs (IgG: n = 82, 22% or IgM: n = 61, 16%) 25,27 and two studies [ n = 166, 44%] evaluated only HEV RNA 26,28 . No study evaluated HEV Ag.…”

Section: Resultsmentioning

confidence: 99%

“…The prevalence of anti‐HEV IgG, IgM and HEV RNA ranged: from 3.4% to 4.3%, 10,25 1.64% to 2.9% 10,27 and 2.9% to 20%, 10,26,28 respectively. Based on the available data, 10 (4.2%) of the 236 LT patients with abnormal LFTs were positive for HEV RNA.…”

Section: Resultsmentioning

confidence: 99%

“…Two European studies including 152 recipients were published between 2009 and 2014 10,25 [one evaluated only anti‐HEV IgG and one evaluated both HEV Abs (IgM and IgG) and HEV RNA], while three studies (2 from Europe and 1 from Hong Kong) including 227 recipients were published between 2015 and 2020 26–28 : (one evaluated only anti‐HEV IgM and two evaluated only HEV RNA). In total, HEV RNA was evaluated in 70 patients (46.1%) and 166 patients (73.1%) in studies published between 2009 and 2014 and between 2015 and 2020, respectively.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Epidemiology and treatment of hepatitis E in the liver transplantation setting: A literature review

Markakis

Papatheodoridis

2022

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Hepatitis E virus (HEV) is a common cause of acute hepatitis in developing countries, but it can also take a chronic course especially in immunocompromised patients. Its epidemiology after liver transplantation (LT) is hard to assess and treatment options are still explored. Between 2009 and 2020, literature reporting HEV prevalence and treatment in LT recipients was searched and a synthesis was attempted. Sixteen studies reported HEV prevalence in consecutive LT patients: HEV RNA positivity ranged between 0%–1.4% and 0%–7.7% for Western and Eastern cohorts, respectively. In studies published between 2009–2014 and 2015–2020, HEV RNA positivity ranged between 0.35%–1.3% (all European) and 0%–7.7% (European: 0%–1.4%), respectively. Five studies evaluated HEV prevalence in LT recipients with abnormal liver enzymes: HEV RNA positivity was 2.9% in studies published between 2009 and 2014 and from 3.5% to 20% in studies published between 2015 and 2020. Twenty‐seven studies reported HEV treatment in LT recipients: sustained virologic response was achieved in 15% by immunosuppression reduction alone and in 83% of cases by ribavirin regiments. Chronic HEV infection is affecting LT recipients, mostly those with abnormal liver enzymes and in Eastern countries. HEV diagnoses should be based on PCR techniques. Successful treatment can be achieved with ribavirin in most cases.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Epidemiology and treatment of hepatitis E in the liver transplantation setting: A literature review

Markakis

Papatheodoridis

2022

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

Hepatitis E Virus in the Iberian Peninsula: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

One of the most frequent causes of acute viral hepatitis is hepatitis E virus (HEV) causing 20 million infections worldwide each year and 44,000 deaths. Studies on HEV in the Iberian Peninsula have been increasing through time with HEV infection being identified in humans and animals. The aim of the present systematic review was to compile and evaluate all the published data on HEV from studies performed in humans, animals and environmental samples in the Iberian Peninsula. The electronic databases Mendeley, PubMed, Scopus, and Web of Science were thoroughly searched, and research published up until February 01, 2023 were included. Resulting in a total of 151 eligible papers by full reading and application of PRISMA exclusion/inclusion criteria. Overall, the present review shows that several HEV genotypes, namely HEV-1, 3, 4, and 6 as well as Rocahepevirus, are circulating in humans, animals, and in the environment in the Iberian Peninsula. HEV-3 was the most common genotype circulating in humans in Portugal and Spain, as expected for developed countries, with HEV-1 only being detected in travelers and emigrants from HEV endemic regions. Spain is the biggest pork producer in Europe and given the high circulation of HEV in pigs, with HEV-3 being primarily associated to zoonotic transmission through consumption of swine meat and meat products, in our opinion, the introduction of an HEV surveillance system in swine and inclusion of HEV in diagnostic routines for acute and chronic human hepatitis would be important. Additionally, we propose that establishing a monitoring mechanism for HEV is crucial in order to gain a comprehensive understanding of the prevalence of this illness and the various strains present in the Iberian Peninsula, as well as their potential impact on public health.

show abstract

Journal Summary: Hepatitis E Virus Infection after Liver Transplantation

Thandassery,

Kaur,

Sharma

2023

Journal of Gastrointestinal Infections

View full text Add to dashboard Cite

In a recent prospective multicenter cross-sectional study, Samala et al studied the seroprevalence of hepatitis E virus (HEV) in waitlist and post-transplant patients in the United States. Large multicenter studies regarding HEV infection in the transplant cohort are lacking in the United States, and this prospective multicenter cross-sectional study described higher-than-expected HEV seroprevalence. 1 They studied 456 participants (224 had solid organ transplants, and 232 were on the waiting list). Subjects (above 18 years) after organ transplant and those on the waiting list matched for age, organ, as well as transplant center were enrolled. Organs transplanted include liver, intestine, kidney, and liver-kidney. Among post-transplant patients, those after 1 year of transplantation were included, as they were likely on a stable immunosuppressive regimen. Enrolment of transplant recipients was stratified based on the site and the number of years post-transplant: 1, 2, and more than 3 years.The seropositivity of HEV infection for the whole study groups was 20.2%. The seropositivity was higher in the posttransplant group compared with the waitlist group. In the entire study group, HEV seropositive status was associated with higher age and organ transplantation. In the posttransplant group, older age, calcineurin inhibitor use, and history of graft hepatitis were associated with seropositivity. Authors suggested that HEV infection should be suspected in transplant recipients under evaluation with abnormal liver function tests (LFTs). However, they also noted that detection of HEV-RNA was rare, indicating that development of chronic HEV infection is not common in patients after organ transplantation in the United States. Other studies from the United States are usually limited retrospective studies and mainly included only kidney transplant patients.

show abstract

Ribavirin for Chronic Hepatitis E in Liver-Transplant Setting: A Safe and Highly Effective Therapy

Cited by 5 publications

References 4 publications

Epidemiology and treatment of hepatitis E in the liver transplantation setting: A literature review

Epidemiology and treatment of hepatitis E in the liver transplantation setting: A literature review

Hepatitis E Virus in the Iberian Peninsula: A Systematic Review

Journal Summary: Hepatitis E Virus Infection after Liver Transplantation

Contact Info

Product

Resources

About